Liminatus Pharma, Inc. (LIMN): Entry into a Material Definitive Agreement
Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On November 2, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with a non-U.S. investor, pursuant to which such investor agreed to subscribe for, and the Compan
- Instrument
- common stock
- Gross proceeds
- $650,002.50
- Shares
- 260,001 shares
- Price per share
- $2.50 per share
- Use of proceeds
- working capital and general corporate purposes
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The raise provides modest liquidity but introduces dilution; investors may watch the registration progress.
Market read
A micro‑cap equity raise with limited price impact; primarily relevant to LIMN shareholders and potential new investors.
What to watch
Potential strategic partnership with the non‑U.S. investor could bring future opportunities beyond the cash amount.
Background
SEC Form 8‑K filing reports a private placement under Regulation D and S, with a commitment to register the shares for resale within 60 days.
Ticker impact
Liminatus Pharma disclosed a private placement of 260,001 shares at $2.50 each, raising $650k for working capital.
likely slight pressure as the market prices in dilution from the new shares
The 8‑K is the first public disclosure of the raise; the amount is small relative to market cap, so impact is limited.
Market effects
Minimal effect on the broader biotech/pharma sector; only a micro‑cap specific event.
No significant regional impact; the filing is U.S. focused.
Low global relevance; limited to investors in LIMN.
Counterpoint
If the capital is deployed effectively, the infusion could support growth and offset dilution concerns.
Key entities
- companyLiminatus Pharma, Inc.
Biopharmaceutical company issuing new shares.
- investorNon‑U.S. investor
Subscriber to the private placement.

